AML: acute myeloid leukemia; BCMA:B-cell maturation antigen;  GvHD: graft-versus-host disease; mCRC: metastatic colorectal cancer; MDS: myelodysplastic syndrome; MM: multiple myeloma; NKG2D: Natural killer group 2D; PoC: proof-of-concept; shARC: shRNA armored CAR; shRNA: short hairpin ribonucleic acid; TIM: T-cell receptor inhibitory molecule

# Evaluated in the Phase I studies THINK NCT03018405, LINK NCT03370198, SHRINK NCT03310008 and DEPLETHINK NCT03466320; ## Evaluated in the Phase I study CYCLE-1 NCT04167696; § Evaluated in the Phase I studies alloSHRINK NCT03692429, and KEYNOTE-B79 NCT04991948; §§ Evaluated in the Phase I study IMMUNICY-1 NCT04613557